Encoded Therapeutics ETX101 Receives FDA Breakthrough Therapy Designation for Dravet Syndrome
Encoded Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ETX101 for the treatment of SCN1A-positive Dravet syndrome.
This designation adds to the Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations previously awarded by the FDA.
The Breakthrough Therapy Designation is intended to speed up the development and review of treatments for serious or life-threatening conditions where early clinical evidence suggests a substantial improvement over existing options.
The designation allows for closer interaction with the FDA, including more frequent regulatory guidance and the potential for priority review.
The decision is supported by data from ongoing Phase 1/2 studies, which have shown sustained reductions in seizure frequency and improvements in neurodevelopment following a single administration of ETX101.
Dravet syndrome is a rare and severe genetic epilepsy that begins in infancy and is most often caused by mutations in the SCN1A gene.
The condition is associated with difficult-to-control seizures and long-term cognitive, behavioural, and motor challenges. Current treatments mainly manage symptoms and do not address the underlying genetic cause.
ETX101 is an investigational gene regulation therapy designed to increase SCN1A gene expression through a one-time intracerebroventricular injection, with the aim of providing long-lasting benefit.
